IMPLANET: Successful First JAZZ Cap® Surgeries in the US

  • First procedures in the US with JAZZ Cap®, the proprietary solution
    addressing a potential market of USD2.5 billion 1
  • Secure and protect pedicle screws in poor quality bone

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Euronext Growth: ALIMP, FR0010458729, eligible for PEA-PME
equity savings plans) (Paris:ALIMP) (OTCQX:IMPZY), a medical technology
company specializing in vertebral and knee surgery implants, is
announcing the successful results of the first surgeries using JAZZ Cap®
in the United States.

Following 510(k) clearance in March 2019, the first JAZZ Cap® procedures
have been successfully completed by fellowship trained orthopaedic spine
surgeon Chi Lim, MD in Spartanburg, SC.

JAZZ Cap® is a unique and complete proprietary solution for securing
screws in poor quality bone – a factor in 10% to 30% of vertebral fusion
cases in adult patients2.

Chi Lim, MD of Carolina Orthopaedic & Neurosurgical Associates, said: “I
have been using Implanet’s Jazz Band implants with excellent results in
complex adult deformity indications. The arrival of JAZZ Cap® as part of
the Implanet band range is a major breakthrough in securing and
protecting screws in poor quality bone. This new implant was easy to use
during the first surgeries and has provided encouraging early
post-operative clinical results. We will now follow these patients to
confirm the long term outcomes. In my opinion, JAZZ Cap® will quickly
become an essential implant for spine surgeons.”

Ludovic Lastennet, Implanet’s Chief Executive Officer, commented: “I
am excited to have personally attended Dr. Lim’s initial Jazz Cap®
procedures. The successful completion of these first surgeries represent
a significant step for the development of our company, opening a unique
opportunity in the US degenerative spine market. We anticipate JAZZ Cap®
will become a significant alternative to cement augmented pedicle
screws. Full market release of the technology is scheduled for
September, with a global presentation at the North American Spine
Society Annual Meeting in Chicago.”

Convocation to the General Shareholders’ Meeting on June11, 2019: IMPLANET’s
shareholders are invited to the General Shareholders’ meeting which will
be held on June 11, 2019 at 2:00 pm at the Company’s registered office
located Allée F. Magendie – Technopole Bordeaux Montesquieu – 33650
Martillac – France.

The documents related to the General Meeting are available on the
Company’s website (

The shareholders can vote:

  • by internet via the Votaccess service,
  • by absentee voting,
  • by proxy voting,
  • or attend physically the General Meeting.

A guide which outlines how to vote, and particularly how to vote by
internet (only in French) is available on the company’s website. The
shareholders can also contact the Investor Relations team by email for
any question concerning the ways of voting: [email protected].

If the quorum is not reached following the first convocation, a second
meeting will be held on June 25, 2019 at 2:00 pm at the Company’s
registered office located Allée F. Magendie – Technopole Bordeaux
Montesquieu – 33650 Martillac – France.

Next congress: Come and meet us at the annual SFCR congress for
2019, from June 13 through June 15, 2019 in Strasbourg, France Stand:
42, Website:

Next press release: 2019 first half revenue, 10 July after market

About Implanet

Founded in 2007, Implanet is a medical technology company that
manufactures high-quality implants for orthopedic surgery. Its flagship
product, the Jazz® latest-generation implant, aims to treat spinal
pathologies requiring vertebral fusion surgery. Implanet’s
tried-and-tested orthopedic platform, which is based on perfect control
over the traceability of its products, provides it with a proven ability
to promote this innovation. Protected by four families of international
patents, JAZZ® has obtained 510(k) regulatory clearance from the Food
and Drug Administration (FDA) in the United States and the CE mark.
Implanet employs 38 staff and recorded 2018 sales of €6.7 million. For
further information, please visit
Based near Bordeaux in France, Implanet established a US subsidiary in
Boston in 2013. Implanet is listed on Euronext™ Growth market in Paris.
The Company would like to remind that the table for monitoring the
equity line (OCA, OCAPI, BSA) and the number of shares outstanding, is
available on its website:


This press release contains forward-looking statements concerning
Implanet and its activities. Such forward looking statements are based
on assumptions that Implanet considers to be reasonable. However, there
can be no assurance that the anticipated events contained in such
forward-looking statements will occur. Forward- looking statements are
subject to numerous risks and uncertainties including the risks set
forth in the registration document of Implanet registered by the French
Financial Markets Authority (Autorité des marchés financiers (AMF)) on
April 16, 2018 under number D.18-0337 and available on the Company’s
website (,
and to the development of economic situation, financial markets, and the
markets in which Implanet operates. The forward-looking statements
contained in this release are also subject to risks unknown to Implanet
or that Implanet does not consider material at this time. The
realization of all or part of these risks could lead to actual results,
financial conditions, performances or achievements by Implanet that
differ significantly from the results, financial conditions,
performances or achievements expressed in such forward-looking
statements. This press release and the information it contains do not
constitute an offer to sell or to subscribe for, or a solicitation of an
order to purchase or subscribe for Implanet shares in any country.

1 Sources: i-Data 2010; D. K. Chin et al. Osteoporos Int
(2007) 18:1219–1224; Company; 2015 Health Advances study
Source: 2015 Health Advances study


Ludovic Lastennet, CEO
David Dieumegard, CFO
+33(0)5 57 99 55 55
[email protected]

Investor Relations
Sandrine Boussard-Gallien
+33 (0)1 44 71 94 94
[email protected]

Media Relations
Nicolas Merigeau
Tel.: +33 (0)1 44
71 94 94
[email protected]

error: Content is protected !!